Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting Phase 1 / 2 Trials for CUDC-907 (DB11891)

IndicationStatusPhase
DBCOND0118156 (Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01742988Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaTreatment